Cerba Research is uniquely positioned to support your cell & gene therapy trial with a wide range of in-house laboratory services, supported by bespoke logistics solutions. We are also able to support sponsors with their assay development, including our regulatory and IVDR certification capabilities. One IVDR example is related to AAV ( ADA) ELISA assay.

Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

With Cerba’s network spanning five continents, team up with our experienced scientists to generate early insights and direct the course of your complex trial.

Our locations consist of cutting-edge laboratories that provide a full portfolio of specialty laboratory testing, anchored by seven centers in the Americas, Europe, Africa, and Asia-Pacific regions. With consistent, high-quality data and a road map to the patients you need, we empower you to develop personalized medicines and diagnostic solutions that will change lives worldwide.

Discover our Australia capabilities